Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13
Chemomab Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
Chemomab Therapeutics Analyst Ratings
Chemomab Therapeutics Analyst Ratings
Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target
Chemomab Therapeutics Analyst Ratings
Oppenheimer Reaffirms Their Hold Rating on Chemomab Therapeutics (CMMB)
Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7
Chemomab Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Veralto Corporation (VLTO) and Chemomab Therapeutics (CMMB)
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $7 From $12, Maintains Outperform Rating
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $7
No Data
No Data